These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 22812557

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M, Hollander A, Weiland O, Jönsson B.
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [Abstract] [Full Text] [Related]

  • 3. [Antiviral therapy of hepatitis C].
    Erhardt A, Petry W, Ebel M, Jablonowski H, Heintges T, Häussinger D.
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [Abstract] [Full Text] [Related]

  • 4. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
    Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS.
    Am J Gastroenterol; 2002 Sep; 97(9):2432-40. PubMed ID: 12358269
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
    Smith JP.
    Pharmacotherapy; 2008 Sep; 28(9):1151-61. PubMed ID: 18752386
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
    Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U.
    J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
    [Abstract] [Full Text] [Related]

  • 9. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
    Main J.
    J Hepatol; 1995 Jan; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Advances in the treatment of hepatitis C.
    Lawrence SP.
    Adv Intern Med; 2000 Jan; 45():65-105. PubMed ID: 10635046
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [Abstract] [Full Text] [Related]

  • 16. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
    Merli M, Giannelli V, Gentili F, Giusto M, Simmaco M, Lionetto L, Corradini SG, Biliotti E, Attili AF, Rossi M, Taliani G.
    Antivir Ther; 2011 Jun; 16(6):879-85. PubMed ID: 21900720
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transient corneal microcysts associated with interferon therapy.
    Fracht HU, Harvey TJ, Bennett TJ.
    Cornea; 2005 May; 24(4):480-1. PubMed ID: 15829809
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.